{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myxofibrosarcoma+%28MFS%29",
    "query": {
      "condition": "Myxofibrosarcoma (MFS)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T20:14:20.585Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06789172",
      "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumours",
        "Sarcoma",
        "HNSCC",
        "Non Small Cell Lung Cancer",
        "NSCLC",
        "Colorectal Cancer (CRC)",
        "Myxofibrosarcoma (MFS)",
        "Solitary Fibrous Tumors",
        "Dedifferentiated Liposarcoma",
        "Undifferentiated Pleomorphic Sarcoma (UPS)",
        "Leiomyosarcoma",
        "Leiomyosarcoma (LMS)",
        "Gastric Cancer (GC)",
        "Gastric Cancer Adenocarcinoma Metastatic",
        "Gastric / Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "OKN4395",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Fasting",
          "type": "OTHER"
        },
        {
          "name": "Fed",
          "type": "OTHER"
        },
        {
          "name": "H2 Receptor Antagonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "Epkin",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2025-01-23",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-06-25T20:14:20.585Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Santa Monica, California • Houston, Texas",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06789172"
    }
  ]
}